论文部分内容阅读
目的:探讨卵巢癌患者的纤维蛋白原水平与铂类药物化疗方案治疗效应的相关性。方法:纳入91例卵巢癌患者和同期95例良性卵巢肿瘤患者,分析术前血浆纤维蛋白原水平和临床病理参数以及患者化疗效应的关联。结果:36.26%(33/91)的卵巢癌患者呈现高纤维蛋白原水平(>4.0 g·L~(-1))。卵巢癌患者纤维蛋白原水平升高与卵巢癌(FIGO)分期存在显著相关性(P<0.05),但与年龄、病理学级别不相关(P>0.05)。患者发生高纤维蛋白原血症与血清肿瘤抗原CA125水平升高并不存在相关性(P>0.05)。高纤维蛋白原血症的患者出现化疗耐药的比例显著高于正常水平患者(P<0.05),高纤维蛋白原水平的OR值为3.571,95%CI为1.276~10.000,提示高纤维蛋白原水平是化疗抵抗的危险因素。结论:本研究表明,卵巢癌患者呈现高纤维蛋白原水平可能预示着铂类药物化疗反应差,是一个与血清CA-125不相关的潜在预后因素。
Objective: To investigate the correlation between the fibrinogen level in patients with ovarian cancer and the therapeutic effect of platinum-based chemotherapy regimens. Methods: Totally 91 patients with ovarian cancer and 95 patients with benign ovarian tumors were included in the study. Preoperative plasma fibrinogen levels, clinicopathological parameters and chemosensitivity were analyzed. Results: 36.26% (33/91) of patients with ovarian cancer showed high fibrinogen levels (> 4.0 g · L -1). The level of fibrinogen in patients with ovarian cancer was significantly correlated with the stage of ovarian cancer (FIGO) (P <0.05), but not with age and pathological grade (P> 0.05). There was no correlation between hyperfibrinogenemia and serum CA125 level (P> 0.05). The patients with high fibrinogen showed a significantly higher rate of chemoresistance than those with normal fibrosis (P <0.05). The OR of high fibrinogen was 3.571 and the 95% CI was 1.276-10.000, suggesting that high fibrinogen Level is a risk factor for chemotherapy resistance. CONCLUSIONS: This study shows that the presence of high fibrinogen levels in patients with ovarian cancer may indicate a poor response to chemotherapy with platinum-based drugs and is a potential prognostic factor unrelated to serum CA-125.